Tag: ALKS

Shares of Alkermes Soar on MDD Treatment Potential (ALKS)

Shares of Alkermes Plc (NASDAQ: ALKS) skyrocketed 16% in regular trading hours on Wednesday after the biopharmaceutical company said that its stage-2 clinical trial on the  unbranded drug called ALKS 5461 showed that it was effective in treating patients suffering from major depressive disorder (MDD). In a statement, the Company said that study conducted among 142 patients showed that the treatment ALKS 5461, which is a  one-a day, non-addictive oral medicine, “significantly reduced” depressive symptoms among patients.

Continue reading Shares of Alkermes Soar on MDD Treatment Potential (ALKS)

Major Movers on April 17; ALKS, CSX, BAC, MAT, AAPL, CAT

Alkermes Plc (NASDAQ: ALKS) rallied after the company said its mid-stage clinical trial of the drug ALKS 5451, meant to cure depressive disorders, showed it was capable of “significantly reducing” symptoms of depression. The Company said that it carried studies on 142 patients. Based on the outcome of clinical trials, the Company now intends to hold a meeting with the U.S Food and Drug Administration (FDA) and commence later stage studies.

Continue reading Major Movers on April 17; ALKS, CSX, BAC, MAT, AAPL, CAT